WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2022.
Second Quarter 2022 Highlights
“We delivered another quarter of outstanding financial performance,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Our proven growth strategy and PPI Business System enabled us to deliver exceptional results across our business and we continue to see the benefit of our strategic investments to enhance our unique customer value proposition. The integration of our clinical research business is going very well, the business is performing at a high level and the outlook for long-term synergies is very compelling.”
Casper added, “Our team continues to execute well and we’re in a very strong position at the halfway point of the year and on track to deliver another outstanding year for Thermo Fisher.”
Second Quarter 2022
Revenue for the quarter grew 18% to $10.97 billion in 2022. Organic revenue growth was 3%; acquisitions increased revenue by 19% and currency translation decreased revenue by 4%. Core organic revenue growth was 13%. COVID-19 testing revenue was $0.63 billion.
GAAP Earnings Results
GAAP diluted EPS in the second quarter of 2022 was $4.22, versus $4.61 in the same quarter last year. GAAP operating income for the second quarter of 2022 was $2.00 billion, compared with $2.16 billion in the year-ago quarter. GAAP operating margin was 18.2%, compared with 23.3% in the second quarter of 2021.
Non-GAAP Earnings Results
Adjusted EPS in the second quarter of 2022 was $5.51, versus $5.60 in the second quarter of 2021. Adjusted operating income for the second quarter of 2022 was $2.61 billion, compared with $2.69 billion in the year-ago quarter. Adjusted operating margin was 23.7%, compared with 29.0% in the second quarter of 2021.
Annual Guidance for 2022
The company will provide updated 2022 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Daylight Time.
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today, July 28, 2022, at 8:30 a.m. Eastern Daylight Time. To listen, dial (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The conference ID is 512129. You may also listen to the call live on our website, www.thermofisher.com, by clicking on “Investors.” You will find this press release, including the accompanying reconciliation of non-GAAP financial measures and related information, in that section of our website under “Financials.” An audio archive of the call will be available under “News & Events” through Friday, August 12, 2022.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Three Months Ended
July 2,
% of
July 3,
% of
(In millions except per share amounts)
2022
Revenues
2021
Revenues
Revenues
$
10,970
$
9,273
Costs and operating expenses:
Cost of revenues (a)
6,240
56.9
%
4,585
49.4
%
Selling, general and administrative expenses (b)
1,740
15.9
%
1,614
17.4
%
Amortization of acquisition-related intangible assets
600
5.5
%
449
4.8
%
Research and development expenses
365
3.3
%
343
3.7
%
Restructuring and other costs (c)
24
0.2
%
119
1.3
%
8,969
81.8
%
7,110
76.7
%
Operating income
2,001
18.2
%
2,163
23.3
%
Interest income
36
11
Interest expense
(148
)
(122
)
Other income/(expense) (d)
28
(3
)
Income before income taxes
1,917
2,049
Provision for income taxes (e)
(198
)
(219
)
Equity in earnings/(losses) of unconsolidated entities
(51
)
(1
)
Net income
1,668
1,829
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest
4
1
Net income attributable to Thermo Fisher Scientific Inc.
$
1,664
15.2
%
$
1,828
19.7
%
Earnings per share attributable to Thermo Fisher Scientific Inc.:
Basic
$
4.25
$
4.65
Diluted
$
4.22
$
4.61
Weighted average shares:
Basic
392
393
Diluted
394
396
Reconciliation of adjusted operating income and adjusted operating margin
GAAP operating income
$
2,001
18.2
%
$
2,163
23.3
%
Cost of revenues adjustments (a)
8
0.1
%
—
0.0
%
Selling, general and administrative expenses adjustments (b)
(28
)
-0.3
%
(42
)
-0.4
%
Restructuring and other costs (c)
24
0.2
%
119
1.3
%
Amortization of acquisition-related intangible assets
600
5.5
%
449
4.8
%
Adjusted operating income (non-GAAP measure)
$
2,605
23.7
%
$
2,689
29.0
%
Reconciliation of adjusted net income
GAAP net income attributable to Thermo Fisher Scientific Inc.
$
1,664
$
1,828
Cost of revenues adjustments (a)
8
—
Selling, general and administrative expenses adjustments (b)
(28
)
(42
)
Restructuring and other costs (c)
24
119
Amortization of acquisition-related intangible assets
600
449
Other income/expense adjustments (d)
(18
)
8
Provision for income taxes adjustments (e)
(127
)
(142
)
Equity in earnings/losses of unconsolidated entities
51
1
Adjusted net income (non-GAAP measure)
$
2,174
$
2,221
Reconciliation of adjusted earnings per share
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc.
$
4.22
$
4.61
Cost of revenues adjustments (a)
0.02
0.00
Selling, general and administrative expenses adjustments (b)
(0.07
)
(0.10
)
Restructuring and other costs (c)
0.06
0.30
Amortization of acquisition-related intangible assets
1.52
1.13
Other income/expense adjustments (d)
(0.05
)
0.02
Provision for income taxes adjustments (e)
(0.32
)
(0.36
)
Equity in earnings/losses of unconsolidated entities
0.13
0.00
Adjusted EPS (non-GAAP measure)
$
5.51
$
5.60
Reconciliation of free cash flow
GAAP net cash provided by operating activities
$
1,528
$
2,227
Purchases of property, plant and equipment
(506
)
(540
)
Proceeds from sale of property, plant and equipment
12
—
Free cash flow (non-GAAP measure)
$
1,034
$
1,687
Segment data
Three Months Ended
July 2,
% of
July 3,
% of
(In millions)
2022
Revenues
2021
Revenues
Revenues
Life Sciences Solutions
$
3,292
30.0
%
$
3,557
38.4
%
Analytical Instruments
1,607
14.6
%
1,481
16.0
%
Specialty Diagnostics
1,101
10.0
%
1,235
13.3
%
Laboratory Products and Biopharma Services
5,537
50.5
%
3,583
38.6
%
Eliminations
(567
)
-5.1
%
(583
)
-6.3
%
Consolidated revenues
$
10,970
100.0
%
$
9,273
100.0
%
Operating income and operating margin
Life Sciences Solutions
$
1,327
40.3
%
$
1,718
48.3
%
Analytical Instruments
344
21.4
%
280
18.9
%
Specialty Diagnostics
243
22.1
%
245
19.9
%
Laboratory Products and Biopharma Services
691
12.5
%
446
12.4
%
Subtotal reportable segments
2,605
23.7
%
2,689
29.0
%
Cost of revenues adjustments (a)
(8
)
-0.1
%
—
0.0
%
Selling, general and administrative expenses adjustments (b)
28
0.3
%
42
0.4
%
Restructuring and other costs (c)
(24
)
-0.2
%
(119
)
-1.3
%
Amortization of acquisition-related intangible assets
(600
)
-5.5
%
(449
)
-4.8
%
GAAP operating income
$
2,001
18.2
%
$
2,163
23.3
%
(a) Adjusted results in 2022 exclude charges for the sale of inventories revalued at the date of acquisition.
(b) Adjusted results in 2022 and 2021 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration.
(c) Adjusted results in 2022 and 2021 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2021 also exclude $110 of charges for impairment of technology.
(d) Adjusted results in 2022 and 2021 exclude net gains/losses on investments. Adjusted results in 2021 also exclude amortization of bridge loan commitment fees related to a pending acquisition.
(e) Adjusted provision for income taxes in 2022 and 2021 excludes incremental tax impacts for the reconciling items between GAAP and adjusted net income, and incremental tax impacts as a result of tax rate/law changes. Adjusted results in 2022 also exclude incremental tax impacts from audit settlements.
Note:
Consolidated depreciation expense is $236 and $211 in 2022 and 2021, respectively.
Three months ended
July 2, 2022
Revenue growth
18 %
Acquisitions
19 %
Currency translation
-4 %
Organic revenue growth
3 %
COVID-19 testing revenue
-11 %
Contribution of PPD to Core organic revenue growth (a)
-1 %
Core organic revenue growth
13 %
(a) Adjustment to include the contribution of PPD to Core organic revenue growth as though the acquisition had occurred on January 1, 2021.
Note:
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
Six months ended
July 2,
% of
July 3,
% of
(In millions except per share amounts)
2022
Revenues
2021
Revenues
Revenues
$
22,788
$
19,179
Costs and operating expenses:
Cost of revenues (a)
12,454
54.7
%
9,142
47.7
%
Selling, general and administrative expenses (b)
3,548
15.6
%
3,157
16.5
%
Amortization of acquisition-related intangible assets
1,209
5.3
%
872
4.5
%
Research and development expenses
729
3.2
%
663
3.5
%
Restructuring and other costs (c)
26
0.1
%
133
0.7
%
17,966
78.8
%
13,967
72.8
%
Operating income
4,822
21.2
%
5,212
27.2
%
Interest income
54
23
Interest expense
(284
)
(247
)
Other income/(expense) (d)
(135
)
(186
)
Income before income taxes
4,457
4,802
Provision for income taxes (e)
(499
)
(635
)
Equity in earnings/(losses) of unconsolidated entities
(70
)
(1
)
Net income
3,888
4,166
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest
9
1
Net income attributable to Thermo Fisher Scientific Inc.
$
3,879
17.0
%
$
4,165
21.7
%
Earnings per share attributable to Thermo Fisher Scientific Inc.:
Basic
$
9.90
$
10.58
Diluted
$
9.83
$
10.50
Weighted average shares:
Basic
392
394
Diluted
394
397
Reconciliation of adjusted operating income and adjusted operating margin
GAAP operating income
$
4,822
21.2
%
$
5,212
27.2
%
Cost of revenues adjustments (a)
19
0.1
%
8
0.0
%
Selling, general and administrative expenses adjustments (b)
(21
)
-0.1
%
(26
)
-0.1
%
Restructuring and other costs (c)
26
0.1
%
133
0.7
%
Amortization of acquisition-related intangible assets
1,209
5.3
%
872
4.5
%
Adjusted operating income (non-GAAP measure)
$
6,055
26.6
%
$
6,199
32.3
%
Reconciliation of adjusted net income
GAAP net income attributable to Thermo Fisher Scientific Inc.
$
3,879
$
4,165
Cost of revenues adjustments (a)
19
8
Selling, general and administrative expenses adjustments (b)
(21
)
(26
)
Restructuring and other costs (c)
26
133
Amortization of acquisition-related intangible assets
1,209
872
Other income/expense adjustments (d)
149
205
Provision for income taxes adjustments (e)
(296
)
(272
)
Equity in earnings/losses of unconsolidated entities
70
1
Adjusted net income (non-GAAP measure)
$
5,035
$
5,086
Reconciliation of adjusted earnings per share
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc.
$
9.83
$
10.50
Cost of revenues adjustments (a)
0.05
0.02
Selling, general and administrative expenses adjustments (b)
(0.05
)
(0.07
)
Restructuring and other costs (c)
0.06
0.34
Amortization of acquisition-related intangible assets
3.06
2.20
Other income/expense adjustments (d)
0.38
0.51
Provision for income taxes adjustments (e)
(0.75
)
(0.69
)
Equity in earnings/losses of unconsolidated entities
0.18
0.00
Adjusted EPS (non-GAAP measure)
$
12.76
$
12.81
Reconciliation of free cash flow
GAAP net cash provided by operating activities
$
3,730
$
4,205
Purchases of property, plant and equipment
(1,146
)
(1,168
)
Proceeds from sale of property, plant and equipment
14
5
Free cash flow (non-GAAP measure)
$
2,598
$
3,042
Segment data
Six months ended
July 2,
% of
July 3,
% of
(In millions)
2022
Revenues
2021
Revenues
Revenues
Life Sciences Solutions
$
7,523
33.0
%
$
7,760
40.5
%
Analytical Instruments
3,125
13.7
%
2,868
15.0
%
Specialty Diagnostics
2,583
11.3
%
2,850
14.9
%
Laboratory Products and Biopharma Services
10,979
48.2
%
7,180
37.4
%
Eliminations
(1,422
)
-6.2
%
(1,479
)
-7.8
%
Consolidated revenues
$
22,788
100.0
%
$
19,179
100.0
%
Operating income and operating margin
Life Sciences Solutions
$
3,503
46.6
%
$
3,997
51.5
%
Analytical Instruments
645
20.6
%
552
19.3
%
Specialty Diagnostics
596
23.1
%
673
23.6
%
Laboratory Products and Biopharma Services
1,311
11.9
%
977
13.6
%
Subtotal reportable segments
6,055
26.6
%
6,199
32.3
%
Cost of revenues adjustments (a)
(19
)
-0.1
%
(8
)
0.0
%
Selling, general and administrative expenses adjustments (b)
21
0.1
%
26
0.1
%
Restructuring and other costs (c)
(26
)
-0.1
%
(133
)
-0.7
%
Amortization of acquisition-related intangible assets
(1,209
)
-5.3
%
(872
)
-4.5
%
GAAP operating income
$
4,822
21.2
%
$
5,212
27.2
%
(a) Adjusted results in 2022 and 2021 exclude charges for the sale of inventories revalued at the date of acquisition.
(b) Adjusted results in 2022 and 2021 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration.
(c) Adjusted results in 2022 and 2021 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2021 also exclude $110 of charges for impairment of acquired technology and $13 of charges for compensation due to employees at recently acquired businesses at the date of acquisition.
(d) Adjusted results in 2022 and 2021 exclude net gains/losses on investments and losses on the early extinguishment of debt. Adjusted results in 2021 also exclude amortization of bridge loan commitment fees related to a pending acquisition.
(e) Adjusted provision for income taxes in 2022 and 2021 excludes incremental tax impacts for the reconciling items between GAAP and adjusted net income, and incremental tax impacts as a result of tax rate/law changes. Adjusted results in 2022 also exclude incremental tax impacts from audit settlements.
Notes:
Consolidated depreciation expense is $486 and $409 in 2022 and 2021, respectively.
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
July 2,
December 31,
(In millions)
2022
2021
Assets
Current assets:
Cash and cash equivalents
$
1,888
$
4,477
Accounts receivable, net
7,745
7,977
Inventories
5,668
5,051
Other current assets
2,799
2,608
Total current assets
18,100
20,113
Property, plant and equipment, net
8,529
8,333
Acquisition-related intangible assets, net
18,578
20,113
Other assets
4,306
4,640
Goodwill
41,066
41,924
Total assets
$
90,579
$
95,123
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations
$
1,010
$
2,537
Other current liabilities
9,987
10,899
Total current liabilities
10,997
13,436
Other long-term liabilities
7,861
8,377
Long-term obligations
29,250
32,333
Redeemable noncontrolling interest
117
122
Total equity
42,354
40,855
Total liabilities, redeemable noncontrolling interest and equity
$
90,579
$
95,123
Condensed Consolidated Statement of Cash Flows (unaudited)
Six months ended
July 2,
July 3,
(In millions)
2022
2021
Operating activities
Net income
$
3,888
$
4,166
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
1,695
1,281
Change in deferred income taxes
(601
)
(307
)
Other non-cash expenses, net
472
512
Changes in assets and liabilities, excluding the effects of acquisitions
(1,724
)
(1,447
)
Net cash provided by operating activities
3,730
4,205
Investing activities
Acquisitions, net of cash acquired
(40
)
(1,425
)
Purchases of property, plant and equipment
(1,146
)
(1,168
)
Proceeds from sale of property, plant and equipment
14
5
Other investing activities, net
83
(36
)
Net cash used in investing activities
(1,089
)
(2,624
)
Financing activities
Repayment of debt
(375
)
(2,803
)
Net proceeds from issuance of commercial paper
1,032
—
Repayment of commercial paper
(3,490
)
—
Purchases of company common stock
(2,000
)
(2,000
)
Dividends paid
(220
)
(190
)
Net proceeds from issuance of company common stock under employee stock plans
51
72
Other financing activities, net
(48
)
(5
)
Net cash used in financing activities
(5,050
)
(4,926
)
Exchange rate effect on cash
(177
)
44
Decrease in cash, cash equivalents and restricted cash
(2,586
)
(3,301
)
Cash, cash equivalents and restricted cash at beginning of period
4,491
10,336
Cash, cash equivalents and restricted cash at end of period
$
1,905
$
7,035
Free cash flow (non-GAAP measure)
$
2,598
$
3,042
Note:
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
Supplemental Information Regarding Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired businesses and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth including the impact of PPD revenue, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions other than PPD and currency translation. We calculate period-to-period Core organic revenue growth by adding to the baseline period PPD’s pre-acquisition revenues from such period. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions, foreign currency translation and/or COVID-19 testing on revenues. In particular, given PPD’s significance relative to our existing businesses, management believes it is appropriate to also present information on a basis that includes PPD pre-acquisition revenues in order to demonstrate the impact PPD has on our current growth profile. Core organic revenue growth amounts are not necessarily indicative of the combined results of operations that would have been realized had the PPD acquisition occurred on January 1, 2021. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.
Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Multimedia Files:
Rafael Tejada
Vice President, Investor Relations
Thermo Fisher Scientific
168 Third Avenue
Waltham, MA USA 02451
781.622.1111
E-mail: investorrelations@thermofisher.com
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.
At Thermo Fisher Scientific Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to Thermo Fisher Scientific Inc. to send you the requested Investor Email Alert updates.
* Required
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
About
Suppliers
Corporate Social Responsibility
Information Security
Investors
Newsroom
Careers
Thermo Scientific
Applied Biosystems
Invitrogen
Fisher Scientific
Unity Lab Services
Patheon
© Copyright Thermo Fisher Scientific Inc. All rights reserved.